<SEC-DOCUMENT>0001178913-19-002571.txt : 20191104
<SEC-HEADER>0001178913-19-002571.hdr.sgml : 20191104
<ACCEPTANCE-DATETIME>20191104071428
ACCESSION NUMBER:		0001178913-19-002571
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20191104
FILED AS OF DATE:		20191104
DATE AS OF CHANGE:		20191104

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			COMPUGEN LTD
		CENTRAL INDEX KEY:			0001119774
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-30902
		FILM NUMBER:		191188243

	BUSINESS ADDRESS:	
		STREET 1:		26 HAROKMIM STREET
		STREET 2:		BUILDING D
		CITY:			HOLON
		STATE:			L3
		ZIP:			5885849
		BUSINESS PHONE:		011-972-3-765-8585

	MAIL ADDRESS:	
		STREET 1:		26 HAROKMIM STREET
		STREET 2:		BUILDING D
		CITY:			HOLON
		STATE:			L3
		ZIP:			5885849
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>zk1923580.htm
<DESCRIPTION>6-K
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: ZKG
         Document created using EDGARfilings PROfile 6.4.0.0
         Copyright 1995 - 2019 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;">
    <div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">UNITED STATES</div>
      <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 14pt; font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">Washington, D.C. 20549</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 14pt; font-weight: bold;">Form 6-K</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16</div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">UNDER THE SECURITIES EXCHANGE ACT OF 1934</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: center; line-height: 1.25;">For the month of November 2019</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: center; line-height: 1.25;">Commission File Number 000-30902</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 16pt; font-weight: bold;">COMPUGEN LTD.</div>
      <div style="text-align: center; line-height: 1.25;">(Translation of registrant&#8217;s name into English)</div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="zb1e2a7ccbd054afd9cc90c4f4ff03717">

          <tr>
            <td style="width: 100%; vertical-align: middle;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 100%; vertical-align: bottom;">
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">26&#160;Harokmim Street</div>
            </td>
          </tr>
          <tr>
            <td style="width: 100%; vertical-align: bottom;">
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">Holon 5885849, Israel</div>
            </td>
          </tr>
          <tr>
            <td style="width: 100%; vertical-align: bottom;">
              <div style="text-align: center; line-height: 1.25;">(Address of Principal Executive Offices)&#160;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25;">Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:</div>
      <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif;"> <br>
      </div>
      <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Form 20-F&#160; &#9746; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Form 40-F&#160; &#9744;</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25;">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):&#160; &#9744;</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25;">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):&#160; &#9744;</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">Compugen Ltd.</div>
      <br>
      <div style="line-height: 1.25;">On November 4, 2019, Compugen Ltd. (the &#8220;<font style="font-weight: bold;">Company</font>&#8221;) issued a press release, a copy of which is furnished as Exhibit 99.1 to this Form 6-K and incorporated by reference herein.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25;">The information contained in the first and second paragraphs and the section titled &#8220;Forward-Looking Statements&#8221; in the press release is hereby incorporated by reference into the Company&#8217;s Registration Statement on
        Form F-3, File No. <font style="background-color: #FFFFFF;">333-233001.</font></div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">Exhibits</div>
      &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <br>
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25;">
          <div>
            <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

                <tr>
                  <td style="width: 90pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
                    <div style="line-height: 1.25;"><u><font style="font-weight: bold;">Exhibit</font></u><font style="font-family: 'Times New Roman', Times, serif; font-weight: bold;"><u> Number</u></font></div>
                  </td>
                  <td style="width: auto; vertical-align: top;">
                    <div><font style="font-weight: bold;"><u>Description of Exhibit</u></font></div>
                  </td>
                </tr>

            </table>
          </div>
        </div>
      </div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25;">
        <div>
          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zeea304c74e7e4cbe8a8480b05e0a1999">

              <tr>
                <td style="width: 90pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;"><a href="exhibit_99-1.htm">99.1</a></td>
                <td style="width: auto; vertical-align: top;">
                  <div><a href="exhibit_99-1.htm">Press Release dated November 4, 2019 &#8211; &#8220;Compugen Announces FDA Clearance of IND Application for COM902&#8221;</a></div>
                </td>
              </tr>

          </table>
        </div>
      </div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">Signatures</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z2c887d32e1bc431793944daee9d2456a">

          <tr>
            <td style="width: 50%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td colspan="3" style="vertical-align: bottom;">
              <div style="line-height: 1.25; font-weight: bold;">COMPUGEN LTD.</div>
            </td>
          </tr>
          <tr>
            <td colspan="4" style="vertical-align: middle;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: bottom;">
              <div style="line-height: 1.25;">Date: November 4, 2019&#160;</div>
            </td>
            <td style="width: 3%; vertical-align: bottom;">
              <div style="line-height: 1.25;">By:&#160;</div>
            </td>
            <td style="width: 35%; vertical-align: bottom; border-bottom: 2px solid black;">
              <div style="line-height: 1.25;">/s/ Eran Ben Dor</div>
            </td>
            <td style="width: 12%; vertical-align: bottom;">
              <div style="text-align: center; line-height: 1.25;">&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: middle;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 3%; vertical-align: middle;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 35%; vertical-align: middle;">
              <div style="line-height: 1.25;">Eran Ben Dor</div>
            </td>
            <td style="width: 12%; vertical-align: middle;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 3%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 35%; vertical-align: bottom;">
              <div style="line-height: 1.25;">General Counsel</div>
            </td>
            <td style="width: 12%; vertical-align: bottom;">
              <div style="text-align: center; line-height: 1.25;">&#160;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25;">
        <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exhibit_99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: ZKG
         Document created using EDGARfilings PROfile 6.4.0.0
         Copyright 1995 - 2019 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;">
    <div style="text-align: right;"><u><font style="font-weight: bold;">Exhibit 99.1</font></u><br>
    </div>
    <div> <br>
    </div>
    <div>
      <div style="background-color: #FFFFFF; line-height: 1.25;">
        <div style="line-height: 1.25;"><img width="125" height="53" src="image0.jpg"></div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
      </div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">FOR IMMEDIATE RELEASE</div>
      <div style="background-color: #FFFFFF; line-height: 1.25;">
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
      </div>
      <div style="background-color: #FFFFFF; line-height: 1.25;">
        <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 12pt; font-weight: bold;">Compugen Announces FDA Clearance of<br>
          IND Application for COM902</div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
      </div>
      <div style="text-align: center; line-height: 1.25; font-style: italic; font-weight: bold;">Phase 1 clinical study in patients with advanced malignancies<br>
        expected to begin in early 2020</div>
      <div style="background-color: #FFFFFF; line-height: 1.25;">
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div style="text-align: center; line-height: 1.25; font-style: italic; font-weight: bold;">Clinical development of COM902 will enable testing the combination treatment<br>
          with COM701, Compugen&#8217;s anti-PVRIG inhibitor</div>
      </div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25;">HOLON, ISRAEL &#8211; November 4, 2019 &#8211; <u>Compugen Ltd.</u>
        (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced that the U.S. Food and Drug Administration has cleared its investigational new drug (IND) application for COM902, its
        immuno-oncology therapeutic antibody targeting TIGIT in patients with advanced malignancies.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25;">Under this IND, the Company intends to initiate a Phase 1 clinical trial in patients with advanced malignancies for whom standard of care
        therapies are currently ineffective. Expected to begin in early 2020, the clinical trial is designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of COM902. The study is planned to be
        conducted at multiple centers in the United States and site selection activities are currently underway.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25;">&#8220;IND clearance for COM902 is an important milestone that marks the third program based on new drug targets we discovered to be evaluated
        in the clinic,&#8221; said Anat Cohen-Dayag, Ph.D., President and CEO of Compugen. &#8220;We believe that TIGIT inhibitors may have an important role in the immunotherapy landscape and that our biology driven approach of combining anti-TIGIT and anti-PVRIG
        inhibitors, with or without PD-1 blockers, has the potential to improve clinical responses in patients who are unresponsive and refractory to currently approved immunotherapies. As the only company with clinical candidates targeting both PVRIG and
        TIGIT, we hold a differentiated position in the crowded immuno-oncology space.&#8221;</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div style="page-break-after: always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="line-height: 1.25;">Dr. Cohen-Dayag continued, &#8220;We are proud of our tremendous progress in recent years, transforming into a clinical-stage company with
        three anticipated Phase 1 programs in the clinic expected in 2020, two of which we are being developed internally. Importantly, these three programs address targets which originated from our unique computational discovery platform, highlighting the
        power and value of our computational capabilities to discover new, potentially significant biological pathways and targets for innovative therapeutics.&#8221;</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25; font-weight: bold;">About COM902</div>
      <div style="line-height: 1.25;">COM902, a high affinity, fully human antibody targeting TIGIT, was developed for combination treatment with COM701. Preclinical data
        demonstrate that TIGIT inhibition, either alone or in combination with other checkpoint inhibitors, can enhance T&#160;cell activation and increase anti-tumor immune responses. Parallel inhibition of TIGIT and PVRIG, the two coinhibitory arms of the
        DNAM-1 axis, results in synergistic effects on effector T&#160;cell function and tumor growth inhibition in various model systems that can be further increased with the addition of PD-1 blockade. Based on preclinical data these combinations may be
        clinically important for enhancing anti-tumor immune response and expanding the patient population responsive to checkpoint inhibition.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25;">Compugen discovered TIGIT in 2009 leveraging its immune checkpoint computational discovery platform through which PVRIG was also
        discovered. The TIGT discovery was published by Compugen in October 2009 in the Proceedings of the National Academy of Sciences (PNAS).</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25; font-weight: bold;">About Compugen</div>
      <div style="line-height: 1.25;">Compugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable, predictive computational
        discovery platforms to identify novel drug targets and develop first-in-class therapeutics in the field of cancer immunotherapy. The Company&#8217;s therapeutic pipeline consists of immuno-oncology programs against novel drug targets it has discovered
        computationally, including T cell immune checkpoints and additional early-stage immune-oncology programs focused largely on myeloid targets. Compugen&#8217;s business model is to selectively enter into collaborations for its novel targets and related
        drug product candidates at various stages of research and development. The Company is headquartered in Israel, with facilities in South San Francisco, CA. Compugen&#8217;s shares are listed on Nasdaq and the Tel Aviv Stock Exchange under the ticker
        symbol CGEN. For additional information, please visit Compugen&#8217;s corporate website at www.cgen.com.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div style="page-break-after: always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="line-height: 1.25; font-weight: bold;">Forward-Looking Statement</div>
      <div style="line-height: 1.25;">This press release contains &#8220;forward-looking statements&#8221; within the meaning of the Private Securities Litigation Reform Act of 1995.
        Forward-looking statements can be identified by the use of terminology such as &#8220;will,&#8221; &#8220;may,&#8221; &#8220;expects,&#8221; &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;potential,&#8221; &#8220;plan,&#8221; &#8220;goal,&#8221; &#8220;estimate,&#8221; &#8220;likely,&#8221; &#8220;should,&#8221; &#8220;confident,&#8221; and &#8220;intends,&#8221; and describe opinions about
        possible future events. These forward-looking statements involve known and unknown risks and uncertainties that may cause the actual results, performance or achievements of Compugen to be materially different from any future results, performance or
        achievements expressed or implied by such forward-looking statements. Among these risks: Compugen&#8217;s business model is substantially dependent on entering into collaboration agreements with third parties and Compugen may not be successful in
        generating adequate revenues or commercializing aspects of its business model. Moreover, the development and commercialization of therapeutic candidates involve many inherent risks, including failure to progress to clinical trials or, if they
        progress to or enter clinical trials, failure to advance through clinical development or receive regulatory approval. These and other factors, including the ability to finance the Company, are more fully discussed in the "Risk Factors" section of
        Compugen&#8217;s most recent Annual Report on Form 20-F as filed with the Securities and Exchange Commission (SEC) as well as other documents that may be subsequently filed by Compugen from time to time with the SEC. In addition, any forward-looking
        statements represent Compugen&#8217;s views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. Compugen does not assume any obligation to update any forward-looking statements unless
        required by law.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25; font-weight: bold;">Company contact:</div>
      <div style="line-height: 1.25;">Elana Holzman</div>
      <div style="line-height: 1.25;">Director, Investor Relations and Corporate Communications</div>
      <div style="line-height: 1.25;">Compugen Ltd.</div>
      <div style="line-height: 1.25;">Email: elanah@cgen.com</div>
      <div style="line-height: 1.25;">Tel: +972 (3) 765-8124</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25; font-weight: bold;">Investor Relations contact:</div>
      <div style="line-height: 1.25;">Bob Yedid</div>
      <div style="line-height: 1.25;">LifeSci Advisors, LLC<br>
        Email: bob@lifesciadvisors.com</div>
      <div style="line-height: 1.25;">Tel: +1 (646) 597-6989</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25;">
        <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image0.jpg
<TEXT>
begin 644 image0.jpg
M_]C_X  02D9)1@ ! 0$ =P!2  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !O 1L# 2(  A$! Q$!_\0
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M8 %/HH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MQEC7MU% 'Q3_ ,*V\:_]"OJG_@.U?8F@:>ND>'=-TY5VBUM8X< =U4 UI44
#?__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
